|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report 2 cases of patients who received sodium glucose cotransporter 2 inhibitors until emergency coronary artery bypass grafting (CABG) and developed euglycaemic ketoacidosis after surgery; they were treated with sugar replenishment and insulin infusion.
|
30968118 |
2019 |
|
Ketosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We diagnosed a rare complication of the SGLT2 inhibitor in a patient with type 2 diabetes in whom uncontrolled metabolic ketoacidosis could be effectively managed via continuous renal replacement therapy.
|
30653152 |
2019 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis.
|
30954957 |
2019 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
On 15 May 2015, the U.S. Food and Drug Administration (FDA) warned that administration of sodium-glucose cotransporter-2 (SGLT2) inhibitors could lead to ketoacidosis in patients with diabetes mellitus.
|
31525753 |
2019 |
|
Ketosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Care is required when prescribing the SGLT2 inhibitor class of medications to people with foot vascular issues or prior amputation, and to insulin users in regard of ketoacidosis.
|
30607467 |
2019 |
|
Ketosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common adverse events associated with SGLT2 inhibitors (such as genital infections or volume depletion) are generally mild and manageable by patients or by primary care physicians, and the risk of rare events (such as ketoacidosis) can be minimized by appropriate patient selection and early recognition of symptoms.
|
31741440 |
2019 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the effects of SGLT2 inhibition to promote ketoacidosis are independent from hyperglucagonemia.
|
30710078 |
2019 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Care should be taken to warn patients about genital fungal infections and to avoid use in people with risk factors for SGLT2 associated ketoacidosis.
|
29320602 |
2018 |
|
Ketosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT2 inhibitors have been associated with genital mycotic infections, increased risk of acute kidney injury, dehydration, orthostatic hypotension, and ketoacidosis.
|
30670968 |
2018 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
|
29144574 |
2018 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Euglycaemic ketoacidosis has been reported after sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment.
|
29074329 |
2018 |
|
Ketosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
: Diabetic patients on SGLT2 inhibitor medications are at risk for ketoacidosis.
|
27717592 |
2017 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FAERS contained 259 reports of acidosis (including 192 reports of ketoacidosis) for SGLT2 inhibitors compared with 477 reports of acidosis for DPP4 inhibitors (including 71 reports of ketoacidosis).
|
28736981 |
2017 |
|
Ketosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the basic metabolism of ketone bodies, the triggers of diabetic ketoacidosis, and potential mechanisms by which SGLT2 inhibitors may facilitate the development of ketosis or ketoacidosis.
|
28099783 |
2017 |
|
Ketosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The sensitivity analysis with continuity correction (inputing one event each in drug and comparator arms of each trial with zero events) suggested a reduced incidence of ketoacidosis in patients treated with SGLT-2 inhibitors (MH-OR 0.65 [0.47-0.90]; p=0.01).
|
28570924 |
2017 |